{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,15]],"date-time":"2026-10-15T16:59:27Z","timestamp":1792083567887,"version":"4.4.0"},"reference-count":110,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2027,2,1]],"date-time":"2027-02-01T00:00:00Z","timestamp":1801440000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2027,2,1]],"date-time":"2027-02-01T00:00:00Z","timestamp":1801440000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2027,2,1]],"date-time":"2027-02-01T00:00:00Z","timestamp":1801440000000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-017"},{"start":{"date-parts":[[2027,2,1]],"date-time":"2027-02-01T00:00:00Z","timestamp":1801440000000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-037"},{"start":{"date-parts":[[2027,2,1]],"date-time":"2027-02-01T00:00:00Z","timestamp":1801440000000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-012"},{"start":{"date-parts":[[2027,2,1]],"date-time":"2027-02-01T00:00:00Z","timestamp":1801440000000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-029"},{"start":{"date-parts":[[2027,2,1]],"date-time":"2027-02-01T00:00:00Z","timestamp":1801440000000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-004"}],"funder":[{"DOI":"10.13039\/501100007446","name":"King Khalid University","doi-asserted-by":"publisher","award":["RGP2\/356\/46"],"award-info":[{"award-number":["RGP2\/356\/46"]}],"id":[{"id":"10.13039\/501100007446","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Clinica Chimica Acta"],"published-print":{"date-parts":[[2027,2]]},"DOI":"10.1016\/j.cca.2026.121290","type":"journal-article","created":{"date-parts":[[2026,8,20]],"date-time":"2026-08-20T07:03:46Z","timestamp":1787209426000},"page":"121290","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":0,"special_numbering":"C","title":["Digital droplet PCR and liquid biopsy in acute myeloid Leukemia: bridging translational research and clinical practice"],"prefix":"10.1016","volume":"593","author":[{"ORCID":"https:\/\/orcid.org\/0000-0001-5481-5617","authenticated-orcid":false,"given":"Amr Ali Mohamed Abdelgawwad","family":"El-Sehrawy","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Mohammad","family":"Abohassan","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Iskandar","family":"Shonazarov","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Haitham Hassan","family":"Abd","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Mirza R.","family":"Baig","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Soumya V.","family":"Menon","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ravi","family":"Sharma","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Swati","family":"Mishra","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Neeraj","family":"Bainsal","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Aseel","family":"Smerat","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"issue":"12","key":"10.1016\/j.cca.2026.121290_bb0005","doi-asserted-by":"crossref","first-page":"1345","DOI":"10.1182\/blood.2022016867","article-title":"Diagnosis and management of AML in adults: 2022 recommendations from an international expert panel on behalf of the ELN","volume":"140","author":"D\u00f6hner","year":"2022","journal-title":"Blood"},{"issue":"11","key":"10.1016\/j.cca.2026.121290_bb0010","doi-asserted-by":"crossref","first-page":"1200","DOI":"10.1182\/blood.2022015850","article-title":"International consensus classification of myeloid neoplasms and acute Leukemias: integrating morphologic, clinical, and genomic data","volume":"140","author":"Arber","year":"2022","journal-title":"Blood"},{"issue":"7","key":"10.1016\/j.cca.2026.121290_bb0015","doi-asserted-by":"crossref","first-page":"1703","DOI":"10.1038\/s41375-022-01613-1","article-title":"The 5th edition of the World Health Organization classification of haematolymphoid tumours: myeloid and histiocytic\/dendritic neoplasms","volume":"36","author":"Khoury","year":"2022","journal-title":"Leukemia"},{"issue":"23","key":"10.1016\/j.cca.2026.121290_bb0020","doi-asserted-by":"crossref","first-page":"2209","DOI":"10.1056\/NEJMoa1516192","article-title":"Genomic classification and prognosis in acute myeloid Leukemia","volume":"374","author":"Papaemmanuil","year":"2016","journal-title":"N. Engl. J. Med."},{"issue":"22","key":"10.1016\/j.cca.2026.121290_bb0025","doi-asserted-by":"crossref","first-page":"2059","DOI":"10.1056\/NEJMoa1301689","article-title":"Genomic and epigenomic landscapes of adult de novo acute myeloid leukemia","volume":"368","author":"Ley","year":"2013","journal-title":"N. Engl. J. Med."},{"issue":"7728","key":"10.1016\/j.cca.2026.121290_bb0030","doi-asserted-by":"crossref","first-page":"526","DOI":"10.1038\/s41586-018-0623-z","article-title":"Functional genomic landscape of acute myeloid leukaemia","volume":"562","author":"Tyner","year":"2018","journal-title":"Nature"},{"issue":"7382","key":"10.1016\/j.cca.2026.121290_bb0035","doi-asserted-by":"crossref","first-page":"506","DOI":"10.1038\/nature10738","article-title":"Clonal evolution in relapsed acute myeloid leukaemia revealed by whole-genome sequencing","volume":"481","author":"Ding","year":"2012","journal-title":"Nature"},{"issue":"7661","key":"10.1016\/j.cca.2026.121290_bb0040","doi-asserted-by":"crossref","first-page":"104","DOI":"10.1038\/nature22993","article-title":"Tracing the origins of relapse in acute myeloid leukaemia to stem cells","volume":"547","author":"Shlush","year":"2017","journal-title":"Nature"},{"issue":"2","key":"10.1016\/j.cca.2026.121290_bb0045","doi-asserted-by":"crossref","first-page":"264","DOI":"10.1016\/j.cell.2012.06.023","article-title":"The origin and evolution of mutations in acute myeloid leukemia","volume":"150","author":"Welch","year":"2012","journal-title":"Cell"},{"issue":"149","key":"10.1016\/j.cca.2026.121290_bb0050","doi-asserted-by":"crossref","DOI":"10.1126\/scitranslmed.3004315","article-title":"Clonal evolution of preleukemic hematopoietic stem cells precedes human acute myeloid leukemia","volume":"4","author":"Jan","year":"2012","journal-title":"Sci. Transl. Med."},{"issue":"7","key":"10.1016\/j.cca.2026.121290_bb0055","doi-asserted-by":"crossref","first-page":"2548","DOI":"10.1073\/pnas.1324297111","article-title":"Preleukemic mutations in human acute myeloid leukemia affect epigenetic regulators and persist in remission","volume":"111","author":"Corces-Zimmerman","year":"2014","journal-title":"Proc. Natl. Acad. Sci. USA"},{"issue":"8","key":"10.1016\/j.cca.2026.121290_bb0060","doi-asserted-by":"crossref","first-page":"811","DOI":"10.1001\/jama.2015.9643","article-title":"Association between mutation clearance after induction therapy and outcomes in acute myeloid Leukemia","volume":"314","author":"Klco","year":"2015","journal-title":"Jama"},{"issue":"26","key":"10.1016\/j.cca.2026.121290_bb0065","doi-asserted-by":"crossref","first-page":"2477","DOI":"10.1056\/NEJMoa1409405","article-title":"Clonal hematopoiesis and blood-cancer risk inferred from blood DNA sequence","volume":"371","author":"Genovese","year":"2014","journal-title":"N. Engl. J. Med."},{"issue":"26","key":"10.1016\/j.cca.2026.121290_bb0070","doi-asserted-by":"crossref","first-page":"2488","DOI":"10.1056\/NEJMoa1408617","article-title":"Age-related clonal hematopoiesis associated with adverse outcomes","volume":"371","author":"Jaiswal","year":"2014","journal-title":"N. Engl. J. Med."},{"issue":"12","key":"10.1016\/j.cca.2026.121290_bb0075","doi-asserted-by":"crossref","first-page":"1472","DOI":"10.1038\/nm.3733","article-title":"Age-related mutations associated with clonal hematopoietic expansion and malignancies","volume":"20","author":"Xie","year":"2014","journal-title":"Nat. Med."},{"issue":"7","key":"10.1016\/j.cca.2026.121290_bb0080","doi-asserted-by":"crossref","first-page":"1598","DOI":"10.1038\/s41375-018-0034-z","article-title":"Persistence of pre-leukemic clones during first remission and risk of relapse in acute myeloid leukemia","volume":"32","author":"Rothenberg-Thurley","year":"2018","journal-title":"Leukemia"},{"issue":"2","key":"10.1016\/j.cca.2026.121290_bb0085","doi-asserted-by":"crossref","DOI":"10.3390\/biomedicines11020359","article-title":"Measurable residual disease and clonal evolution in acute myeloid Leukemia from diagnosis to post-transplant follow-up: the role of next-generation sequencing","volume":"11","author":"Sperotto","year":"2023","journal-title":"Biomedicines"},{"issue":"12","key":"10.1016\/j.cca.2026.121290_bb0090","doi-asserted-by":"crossref","first-page":"1275","DOI":"10.1182\/blood-2017-09-801498","article-title":"Minimal\/measurable residual disease in AML: a consensus document from the European LeukemiaNet MRD working party","volume":"131","author":"Schuurhuis","year":"2018","journal-title":"Blood"},{"issue":"26","key":"10.1016\/j.cca.2026.121290_bb0095","doi-asserted-by":"crossref","first-page":"2753","DOI":"10.1182\/blood.2021013626","article-title":"2021 update on MRD in acute myeloid leukemia: a consensus document from the European LeukemiaNet MRD working party","volume":"138","author":"Heuser","year":"2021","journal-title":"Blood"},{"issue":"8","key":"10.1016\/j.cca.2026.121290_bb0100","doi-asserted-by":"crossref","first-page":"460","DOI":"10.1038\/nrclinonc.2013.100","article-title":"Minimal residual disease in acute myeloid leukaemia","volume":"10","author":"Hourigan","year":"2013","journal-title":"Nat. Rev. Clin. Oncol."},{"issue":"7","key":"10.1016\/j.cca.2026.121290_bb0105","doi-asserted-by":"crossref","first-page":"1482","DOI":"10.1038\/leu.2017.113","article-title":"Measurable residual disease testing in acute myeloid leukaemia","volume":"31","author":"Hourigan","year":"2017","journal-title":"Leukemia"},{"issue":"31","key":"10.1016\/j.cca.2026.121290_bb0110","doi-asserted-by":"crossref","first-page":"3889","DOI":"10.1200\/JCO.2012.45.9628","article-title":"High prognostic impact of flow cytometric minimal residual disease detection in acute myeloid leukemia: data from the HOVON\/SAKK AML 42A study","volume":"31","author":"Terwijn","year":"2013","journal-title":"J. Clin. Oncol."},{"issue":"15","key":"10.1016\/j.cca.2026.121290_bb0115","doi-asserted-by":"crossref","first-page":"1486","DOI":"10.1200\/JCO.2017.76.3425","article-title":"Measurable residual disease at induction redefines partial response in acute myeloid Leukemia and stratifies outcomes in patients at standard risk without NPM1 mutations","volume":"36","author":"Freeman","year":"2018","journal-title":"J. Clin. Oncol."},{"issue":"30","key":"10.1016\/j.cca.2026.121290_bb0120","doi-asserted-by":"crossref","first-page":"4944","DOI":"10.1200\/JCO.2007.15.9814","article-title":"Toward optimization of postremission therapy for residual disease-positive patients with acute myeloid leukemia","volume":"26","author":"Maurillo","year":"2008","journal-title":"J. Clin. Oncol."},{"issue":"9","key":"10.1016\/j.cca.2026.121290_bb0125","doi-asserted-by":"crossref","first-page":"1190","DOI":"10.1200\/JCO.2010.31.8121","article-title":"Impact of pretransplantation minimal residual disease, as detected by multiparametric flow cytometry, on outcome of myeloablative hematopoietic cell transplantation for acute myeloid leukemia","volume":"29","author":"Walter","year":"2011","journal-title":"J. Clin. Oncol."},{"issue":"7","key":"10.1016\/j.cca.2026.121290_bb0130","doi-asserted-by":"crossref","first-page":"1456","DOI":"10.1038\/leu.2016.46","article-title":"Pre- and post-transplant quantification of measurable (\u2019minimal\u2019) residual disease via multiparameter flow cytometry in adult acute myeloid leukemia","volume":"30","author":"Zhou","year":"2016","journal-title":"Leukemia"},{"issue":"4","key":"10.1016\/j.cca.2026.121290_bb0135","first-page":"1044","article-title":"Liquid biopsies in myeloid malignancies","volume":"2","author":"Abdulmawjood","year":"2019","journal-title":"Cancer Drug Resist."},{"key":"10.1016\/j.cca.2026.121290_bb0140","doi-asserted-by":"crossref","DOI":"10.3389\/fonc.2023.1164017","article-title":"Liquid biopsies and minimal residual disease in myeloid malignancies","volume":"13","author":"Allam","year":"2023","journal-title":"Front. Oncol."},{"key":"10.1016\/j.cca.2026.121290_bb0145","doi-asserted-by":"crossref","DOI":"10.3389\/fcell.2020.604391","article-title":"Real-time molecular monitoring in acute myeloid Leukemia with circulating tumor DNA","volume":"8","author":"Thakral","year":"2020","journal-title":"Front. Cell Dev. Biol."},{"issue":"2","key":"10.1016\/j.cca.2026.121290_bb0150","doi-asserted-by":"crossref","first-page":"215","DOI":"10.20892\/j.issn.2095-3941.2016.0025","article-title":"Liquid biopsies for liquid tumors: emerging potential of circulating free nucleic acid evaluation for the management of hematologic malignancies","volume":"13","author":"Hocking","year":"2016","journal-title":"Cancer Biol. Med."},{"issue":"4","key":"10.1016\/j.cca.2026.121290_bb0155","doi-asserted-by":"crossref","first-page":"291","DOI":"10.1111\/ejh.12925","article-title":"Cell-free DNA - minimally invasive marker of hematological malignancies","volume":"99","author":"Kubaczkova","year":"2017","journal-title":"Eur. J. Haematol."},{"issue":"12","key":"10.1016\/j.cca.2026.121290_bb0160","doi-asserted-by":"crossref","first-page":"1685","DOI":"10.1182\/blood-2016-09-740308","article-title":"Molecular disease monitoring using circulating tumor DNA in myelodysplastic syndromes","volume":"129","author":"Yeh","year":"2017","journal-title":"Blood"},{"issue":"9","key":"10.1016\/j.cca.2026.121290_bb0165","doi-asserted-by":"crossref","first-page":"1329","DOI":"10.1111\/cas.12994","article-title":"Peripheral blood cell-free DNA is an alternative tumor DNA source reflecting disease status in myelodysplastic syndromes","volume":"107","author":"Suzuki","year":"2016","journal-title":"Cancer Sci."},{"issue":"4","key":"10.1016\/j.cca.2026.121290_bb0170","doi-asserted-by":"crossref","first-page":"662","DOI":"10.1016\/j.bbrc.2012.02.071","article-title":"Using peripheral blood circulating DNAs to detect CpG global methylation status and genetic mutations in patients with myelodysplastic syndrome","volume":"419","author":"Iriyama","year":"2012","journal-title":"Biochem. Biophys. Res. Commun."},{"issue":"7","key":"10.1016\/j.cca.2026.121290_bb0175","doi-asserted-by":"crossref","first-page":"2799","DOI":"10.1182\/blood-2003-06-1840","article-title":"Relative increase in leukemia-specific DNA in peripheral blood plasma from patients with acute myeloid leukemia and myelodysplasia","volume":"103","author":"Rogers","year":"2004","journal-title":"Blood"},{"issue":"11","key":"10.1016\/j.cca.2026.121290_bb0180","doi-asserted-by":"crossref","first-page":"1651","DOI":"10.1515\/CCLM.2010.311","article-title":"Increased integrity of circulating cell-free DNA in plasma of patients with acute leukemia","volume":"48","author":"Gao","year":"2010","journal-title":"Clin. Chem. Lab. Med."},{"issue":"1","key":"10.1016\/j.cca.2026.121290_bb0185","doi-asserted-by":"crossref","first-page":"17","DOI":"10.7150\/ijms.10144","article-title":"Quantitative detection of circulating nucleophosmin mutations DNA in the plasma of patients with acute myeloid leukemia","volume":"12","author":"Quan","year":"2015","journal-title":"Int. J. Med. Sci."},{"issue":"8","key":"10.1016\/j.cca.2026.121290_bb0190","doi-asserted-by":"crossref","first-page":"1670","DOI":"10.1182\/bloodadvances.2019001156","article-title":"Targeted next-generation sequencing of circulating cell-free DNA vs bone marrow in patients with acute myeloid leukemia","volume":"4","author":"Short","year":"2020","journal-title":"Blood Adv."},{"issue":"25","key":"10.1016\/j.cca.2026.121290_bb0195","doi-asserted-by":"crossref","first-page":"2682","DOI":"10.1182\/blood-2018-10-880690","article-title":"Prognostic impact of circulating tumor DNA status post-allogeneic hematopoietic stem cell transplantation in AML and MDS","volume":"133","author":"Nakamura","year":"2019","journal-title":"Blood"},{"key":"10.1016\/j.cca.2026.121290_bb0200","doi-asserted-by":"crossref","DOI":"10.3389\/fimmu.2024.1252258","article-title":"Detection of minimal residual disease in acute myeloid leukemia: evaluating utility and challenges","volume":"15","author":"\u00c1lvarez","year":"2024","journal-title":"Front. Immunol."},{"issue":"12","key":"10.1016\/j.cca.2026.121290_bb0205","doi-asserted-by":"crossref","DOI":"10.1016\/j.isci.2023.108271","article-title":"Modeling early treatment response in AML from cell-free tumor DNA","volume":"26","author":"Wang","year":"2023","journal-title":"iScience"},{"issue":"1","key":"10.1016\/j.cca.2026.121290_bb0210","doi-asserted-by":"crossref","first-page":"32679","DOI":"10.1038\/s41598-025-20589-3","article-title":"Detection of minimal residual disease in circulating cell-free DNA in acute myeloid leukemia","volume":"15","author":"Sommer","year":"2025","journal-title":"Sci. Rep."},{"issue":"3","key":"10.1016\/j.cca.2026.121290_bb0215","doi-asserted-by":"crossref","DOI":"10.1002\/hem3.70097","article-title":"Cell-free DNA for detection and monitoring of extramedullary AML relapse","volume":"9","author":"Hupe","year":"2025","journal-title":"HemaSphere"},{"issue":"16","key":"10.1016\/j.cca.2026.121290_bb0220","doi-asserted-by":"crossref","first-page":"9236","DOI":"10.1073\/pnas.96.16.9236","article-title":"Digital PCR","volume":"96","author":"Vogelstein","year":"1999","journal-title":"Proc. Natl. Acad. Sci. USA"},{"issue":"2","key":"10.1016\/j.cca.2026.121290_bb0225","doi-asserted-by":"crossref","first-page":"1003","DOI":"10.1021\/ac202578x","article-title":"Evaluation of a droplet digital polymerase chain reaction format for DNA copy number quantification","volume":"84","author":"Pinheiro","year":"2012","journal-title":"Anal. Chem."},{"issue":"10","key":"10.1016\/j.cca.2026.121290_bb0230","doi-asserted-by":"crossref","first-page":"1003","DOI":"10.1038\/nmeth.2633","article-title":"Absolute quantification by droplet digital PCR versus analog real-time PCR","volume":"10","author":"Hindson","year":"2013","journal-title":"Nat. Methods"},{"issue":"6","key":"10.1016\/j.cca.2026.121290_bb0235","doi-asserted-by":"crossref","first-page":"892","DOI":"10.1373\/clinchem.2013.206375","article-title":"The digital MIQE guidelines: minimum information for publication of quantitative digital PCR experiments","volume":"59","author":"Huggett","year":"2013","journal-title":"Clin. Chem."},{"issue":"9","key":"10.1016\/j.cca.2026.121290_bb0240","doi-asserted-by":"crossref","DOI":"10.3390\/ijms20092249","article-title":"Digital PCR in myeloid malignancies: ready to replace quantitative PCR?","volume":"20","author":"Cilloni","year":"2019","journal-title":"Int. J. Mol. Sci."},{"issue":"9","key":"10.1016\/j.cca.2026.121290_bb0245","doi-asserted-by":"crossref","DOI":"10.3390\/ijms21093141","article-title":"Digital PCR: a reliable tool for Analyzing and monitoring hematologic malignancies","volume":"21","author":"Coccaro","year":"2020","journal-title":"Int. J. Mol. Sci."},{"key":"10.1016\/j.cca.2026.121290_bb0250","doi-asserted-by":"crossref","DOI":"10.3389\/fcell.2020.604391","article-title":"Real-time molecular monitoring in acute myeloid leukemia with circulating tumor DNA","volume":"8","author":"Thakral","year":"2020","journal-title":"Front. Cell Dev. Biol."},{"issue":"1","key":"10.1016\/j.cca.2026.121290_bb0255","doi-asserted-by":"crossref","DOI":"10.1038\/srep11295","article-title":"Serum exosome microRNA as a minimally-invasive early biomarker of AML","volume":"5","author":"Hornick","year":"2015","journal-title":"Sci. Rep."},{"issue":"2","key":"10.1016\/j.cca.2026.121290_bb0260","doi-asserted-by":"crossref","first-page":"918","DOI":"10.1158\/0008-5472.CAN-12-2184","article-title":"RNA trafficking by acute myelogenous leukemia exosomes","volume":"73","author":"Huan","year":"2013","journal-title":"Cancer Res."},{"issue":"3","key":"10.1016\/j.cca.2026.121290_bb0265","doi-asserted-by":"crossref","first-page":"575","DOI":"10.1038\/leu.2017.259","article-title":"Acute myeloid leukemia transforms the bone marrow niche into a leukemia-permissive microenvironment through exosome secretion","volume":"32","author":"Kumar","year":"2018","journal-title":"Leukemia"},{"issue":"12","key":"10.1016\/j.cca.2026.121290_bb0270","doi-asserted-by":"crossref","first-page":"1389","DOI":"10.1016\/j.leukres.2015.08.009","article-title":"The impact of standard chemotherapy on miRNA signature in plasma in AML patients","volume":"39","author":"Koutova","year":"2015","journal-title":"Leuk. Res."},{"issue":"8","key":"10.1016\/j.cca.2026.121290_bb0275","doi-asserted-by":"crossref","first-page":"1670","DOI":"10.1182\/bloodadvances.2019001156","article-title":"Targeted next-generation sequencing of circulating cell-free DNA vs bone marrow in patients with acute myeloid leukemia","volume":"4","author":"Short","year":"2020","journal-title":"Blood Adv."},{"issue":"1","key":"10.1016\/j.cca.2026.121290_bb0280","doi-asserted-by":"crossref","first-page":"410","DOI":"10.1186\/s12967-024-05114-w","article-title":"Measurable residual disease monitoring by ddPCR in the early posttransplant period complements the traditional MFC method to predict relapse after HSCT in AML\/MDS: a multicenter retrospective study","volume":"22","author":"Chen","year":"2024","journal-title":"J. Transl. Med."},{"issue":"8","key":"10.1016\/j.cca.2026.121290_bb0285","doi-asserted-by":"crossref","first-page":"1815","DOI":"10.3324\/haematol.2021.279230","article-title":"Utility of plasma cell-free DNA for de novo detection and quantification of clonal hematopoiesis","volume":"107","author":"Gutierrez-Rodrigues","year":"2022","journal-title":"Haematologica"},{"issue":"1","key":"10.1016\/j.cca.2026.121290_bb0290","doi-asserted-by":"crossref","first-page":"8","DOI":"10.1016\/j.bdq.2014.08.001","article-title":"Determining lower limits of detection of digital PCR assays for cancer-related gene mutations","volume":"1","author":"Milbury","year":"2014","journal-title":"Biomol. Detect Quantif."},{"issue":"12","key":"10.1016\/j.cca.2026.121290_bb0295","doi-asserted-by":"crossref","first-page":"1890","DOI":"10.1001\/jamaoncol.2020.4600","article-title":"Association of Measurable Residual Disease with Survival Outcomes in patients with acute myeloid Leukemia: a systematic review and Meta-analysis","volume":"6","author":"Short","year":"2020","journal-title":"JAMA Oncol."},{"issue":"4","key":"10.1016\/j.cca.2026.121290_bb0300","doi-asserted-by":"crossref","first-page":"537","DOI":"10.1016\/j.jmoldx.2017.03.005","article-title":"Minimal residual disease monitoring of acute myeloid Leukemia by massively multiplex digital PCR in patients with NPM1 mutations","volume":"19","author":"Mencia-Trinchant","year":"2017","journal-title":"J. Mol. Diagn."},{"issue":"10","key":"10.1016\/j.cca.2026.121290_bb0305","doi-asserted-by":"crossref","first-page":"1757","DOI":"10.1007\/s00277-018-3373-y","article-title":"Digital droplet PCR-based absolute quantification of pre-transplant NPM1 mutation burden predicts relapse in acute myeloid leukemia patients","volume":"97","author":"Bill","year":"2018","journal-title":"Ann. Hematol."},{"issue":"4","key":"10.1016\/j.cca.2026.121290_bb0310","doi-asserted-by":"crossref","first-page":"664","DOI":"10.1111\/ijlh.13608","article-title":"Comparison of RNA- and DNA-based methods for measurable residual disease analysis in NPM1-mutated acute myeloid leukemia","volume":"43","author":"Pettersson","year":"2021","journal-title":"Int. J. Lab. Hematol."},{"issue":"11","key":"10.1016\/j.cca.2026.121290_bb0315","article-title":"Detection of NPM1 mutations in acute myeloid leukemia by using drop-off droplet digital PCR and its clinical application","volume":"69","author":"Jin","year":"2023","journal-title":"Clin. Lab."},{"issue":"5","key":"10.1016\/j.cca.2026.121290_bb0320","doi-asserted-by":"crossref","first-page":"590","DOI":"10.1111\/j.1365-2141.2004.04952.x","article-title":"WT1 gene expression: an excellent tool for monitoring minimal residual disease in 70% of acute myeloid leukaemia patients - results from a single-Centre study","volume":"125","author":"\u00d8stergaard","year":"2004","journal-title":"Br. J. Haematol."},{"key":"10.1016\/j.cca.2026.121290_bb0325","article-title":"Double drop-off droplet digital PCR (DDO-ddPCR): a novel, versatile tool for mutation screening and residual disease monitoring in acute myeloid leukemia using cellular or cell-free DNA","volume":"23","author":"Rausch","year":"2021","journal-title":"J. Mol. Diagn."},{"issue":"5","key":"10.1016\/j.cca.2026.121290_bb0330","doi-asserted-by":"crossref","first-page":"641","DOI":"10.1515\/cclm-2018-0827","article-title":"Droplet digital PCR for the simultaneous analysis of minimal residual disease and hematopoietic chimerism after allogeneic cell transplantation","volume":"57","author":"Waterhouse","year":"2019","journal-title":"Clin. Chem. Lab. Med."},{"issue":"2","key":"10.1016\/j.cca.2026.121290_bb0335","doi-asserted-by":"crossref","DOI":"10.1371\/journal.pone.0212708","article-title":"Earlier relapse detection after allogeneic haematopoietic stem cell transplantation by chimerism assays: digital PCR versus quantitative real-time PCR of insertion\/deletion polymorphisms","volume":"14","author":"Valero-Garcia","year":"2019","journal-title":"PLoS One"},{"issue":"5","key":"10.1016\/j.cca.2026.121290_bb0340","doi-asserted-by":"crossref","first-page":"1069","DOI":"10.1016\/j.bbmt.2017.12.802","article-title":"Ultra-sensitive droplet digital PCR for the assessment of microchimerism in cellular therapies","volume":"24","author":"Kliman","year":"2018","journal-title":"Biol. Blood Marrow Transplant."},{"issue":"9","key":"10.1016\/j.cca.2026.121290_bb0345","doi-asserted-by":"crossref","DOI":"10.3390\/ijms17091515","article-title":"Digital PCR panel for sensitive hematopoietic chimerism quantification after allogeneic stem cell transplantation","volume":"17","author":"Stahl","year":"2016","journal-title":"Int. J. Mol. Sci."},{"issue":"3","key":"10.1016\/j.cca.2026.121290_bb0350","doi-asserted-by":"crossref","first-page":"102","DOI":"10.4161\/chim.25400","article-title":"Detection and quantification of chimerism by droplet digital PCR","volume":"4","author":"George","year":"2013","journal-title":"Chimerism"},{"issue":"21","key":"10.1016\/j.cca.2026.121290_bb0355","doi-asserted-by":"crossref","first-page":"2228","DOI":"10.1182\/blood.2022015853","article-title":"Genomic profiling for clinical decision making in myeloid neoplasms and acute leukemia","volume":"140","author":"Duncavage","year":"2022","journal-title":"Blood"},{"issue":"3","key":"10.1016\/j.cca.2026.121290_bb0360","doi-asserted-by":"crossref","first-page":"364","DOI":"10.1038\/sj.leu.2401678","article-title":"Use of dual-color interphase FISH for the detection of inv(16) in acute myeloid leukemia at diagnosis, relapse and during follow-up: a study of 23 patients","volume":"14","author":"Mancini","year":"2000","journal-title":"Leukemia"},{"issue":"5","key":"10.1016\/j.cca.2026.121290_bb0365","doi-asserted-by":"crossref","first-page":"1446","DOI":"10.1007\/s12094-022-03042-z","article-title":"Measurable residual disease study through three different methods can anticipate relapse and guide pre-emptive therapy in childhood acute myeloid leukemia","volume":"25","author":"Ramos Elbal","year":"2023","journal-title":"Clin. Transl. Oncol."},{"issue":"2","key":"10.1016\/j.cca.2026.121290_bb0370","doi-asserted-by":"crossref","first-page":"185","DOI":"10.1200\/JCO.2016.67.1875","article-title":"Postinduction minimal residual disease predicts outcome and benefit from allogeneic stem cell transplantation in acute myeloid Leukemia with NPM1 mutation: a study by the acute Leukemia French association group","volume":"35","author":"Balsat","year":"2017","journal-title":"J. Clin. Oncol."},{"issue":"26","key":"10.1016\/j.cca.2026.121290_bb0375","doi-asserted-by":"crossref","first-page":"3041","DOI":"10.1182\/blood.2020005998","article-title":"Impact of gemtuzumab ozogamicin on MRD and relapse risk in patients with NPM1-mutated AML: results from the AMLSG 09-09 trial","volume":"136","author":"Kapp-Schwoerer","year":"2020","journal-title":"Blood"},{"issue":"3","key":"10.1016\/j.cca.2026.121290_bb0380","doi-asserted-by":"crossref","first-page":"254","DOI":"10.1056\/NEJMoa041974","article-title":"Cytoplasmic nucleophosmin in acute myelogenous leukemia with a normal karyotype","volume":"352","author":"Falini","year":"2005","journal-title":"N. Engl. J. Med."},{"issue":"12","key":"10.1016\/j.cca.2026.121290_bb0385","doi-asserted-by":"crossref","first-page":"3733","DOI":"10.1182\/blood-2005-06-2248","article-title":"Nucleophosmin gene mutations are predictors of favorable prognosis in acute myelogenous leukemia with a normal karyotype","volume":"106","author":"Schnittger","year":"2005","journal-title":"Blood"},{"issue":"5","key":"10.1016\/j.cca.2026.121290_bb0390","doi-asserted-by":"crossref","first-page":"371","DOI":"10.1182\/blood.2019002697","article-title":"Impact of NPM1\/FLT3-ITD genotypes defined by the 2017 European LeukemiaNet in patients with acute myeloid leukemia","volume":"135","author":"D\u00f6hner","year":"2020","journal-title":"Blood"},{"issue":"11","key":"10.1016\/j.cca.2026.121290_bb0395","doi-asserted-by":"crossref","DOI":"10.3390\/ijms25115771","article-title":"FLT3-TKD measurable residual disease detection using droplet digital PCR and clinical applications in acute myeloid Leukemia","volume":"25","author":"Li","year":"2024","journal-title":"Int. J. Mol. Sci."},{"issue":"7","key":"10.1016\/j.cca.2026.121290_bb0400","doi-asserted-by":"crossref","DOI":"10.3390\/cancers12071738","article-title":"Digital droplet PCR is a specific and sensitive tool for detecting IDH2 mutations in acute myeloid LeuKemia patients","volume":"12","author":"Grassi","year":"2020","journal-title":"Cancers (Basel)"},{"issue":"4","key":"10.1016\/j.cca.2026.121290_bb0405","doi-asserted-by":"crossref","first-page":"e157","DOI":"10.3324\/haematol.2015.135467","article-title":"Droplet digital polymerase chain reaction for DNMT3A and IDH1\/2 mutations to improve early detection of acute myeloid leukemia relapse after allogeneic hematopoietic stem cell transplantation","volume":"101","author":"Brambati","year":"2016","journal-title":"Haematologica"},{"key":"10.1016\/j.cca.2026.121290_bb0410","doi-asserted-by":"crossref","first-page":"34","DOI":"10.1016\/j.clinbiochem.2018.08.012","article-title":"IDH1 and IDH2 mutations in patients with acute myeloid leukemia: suitable targets for minimal residual disease monitoring?","volume":"61","author":"Petrova","year":"2018","journal-title":"Clin. Biochem."},{"issue":"2","key":"10.1016\/j.cca.2026.121290_bb0415","doi-asserted-by":"crossref","first-page":"305","DOI":"10.3324\/haematol.2018.191148","article-title":"Persistent IDH1\/2 mutations in remission can predict relapse in patients with acute myeloid leukemia","volume":"104","author":"Chi Young","year":"2019","journal-title":"Haematologica"},{"key":"10.1016\/j.cca.2026.121290_bb0420","doi-asserted-by":"crossref","first-page":"161","DOI":"10.1016\/j.clinbiochem.2018.10.005","article-title":"Corrigendum to \u2018IDH1 and IDH2 mutations in patients with acute myeloid leukemia: suitable targets for minimal residual disease monitoring?\u2019 clinical biochemistry 61 (2018) 34-39","volume":"63","author":"Petrova","year":"2019","journal-title":"Clin. Biochem."},{"issue":"6","key":"10.1016\/j.cca.2026.121290_bb0425","doi-asserted-by":"crossref","DOI":"10.1371\/journal.pone.0253386","article-title":"Nucleophosmin1 and isocitrate dehydrogenase 1 and 2 as measurable residual disease markers in acute myeloid leukemia","volume":"16","author":"K\u00f6vy","year":"2021","journal-title":"PLoS One"},{"issue":"9","key":"10.1016\/j.cca.2026.121290_bb0430","doi-asserted-by":"crossref","first-page":"2294","DOI":"10.1182\/bloodadvances.2021004367","article-title":"Posttransplantation MRD monitoring in patients with AML by next-generation sequencing using DTA and non-DTA mutations","volume":"5","author":"Heuser","year":"2021","journal-title":"Blood Adv."},{"key":"10.1016\/j.cca.2026.121290_bb0435","doi-asserted-by":"crossref","first-page":"89","DOI":"10.1016\/j.leukres.2018.04.013","article-title":"Monitoring of clonal evolution of double C-KIT exon 17 mutations by droplet digital PCR in patients with core-binding factor acute myeloid leukemia","volume":"69","author":"Tan","year":"2018","journal-title":"Leuk. Res."},{"issue":"9","key":"10.1016\/j.cca.2026.121290_bb0440","doi-asserted-by":"crossref","first-page":"1891","DOI":"10.1038\/leu.2013.186","article-title":"The importance of relative mutant level for evaluating impact on outcome of KIT, FLT3 and CBL mutations in core-binding factor acute myeloid leukemia","volume":"27","author":"Allen","year":"2013","journal-title":"Leukemia"},{"issue":"12","key":"10.1016\/j.cca.2026.121290_bb0445","doi-asserted-by":"crossref","first-page":"2372","DOI":"10.1182\/blood-2009-09-241075","article-title":"Prevalence and prognostic significance of KIT mutations in pediatric patients with core binding factor AML enrolled on serial pediatric cooperative trials for de novo AML","volume":"115","author":"Pollard","year":"2010","journal-title":"Blood"},{"issue":"9","key":"10.1016\/j.cca.2026.121290_bb0450","doi-asserted-by":"crossref","first-page":"3484","DOI":"10.1172\/JCI91964","article-title":"Ultrasensitive mutation detection identifies rare residual cells causing acute myelogenous leukemia relapse","volume":"127","author":"Parkin","year":"2017","journal-title":"J. Clin. Invest."},{"issue":"6","key":"10.1016\/j.cca.2026.121290_bb0455","doi-asserted-by":"crossref","first-page":"1766","DOI":"10.3324\/haematol.2023.283790","article-title":"Multi-gene measurable residual disease assessed by digital polymerase chain reaction has clinical and biological utility in acute myeloid leukemia patients receiving venetoclax\/azacitidine","volume":"109","author":"Winters","year":"2024","journal-title":"Haematologica"},{"issue":"2","key":"10.1016\/j.cca.2026.121290_bb0460","doi-asserted-by":"crossref","first-page":"103","DOI":"10.1097\/00043426-200302000-00004","article-title":"Real-time quantitative PCR: standardized detection of minimal residual disease in pediatric acute lymphoblastic leukemia. Polymerase chain reaction","volume":"25","author":"Pine","year":"2003","journal-title":"J. Pediatr. Hematol. Oncol."},{"issue":"6","key":"10.1016\/j.cca.2026.121290_bb0465","doi-asserted-by":"crossref","first-page":"2267","DOI":"10.1182\/blood.V88.6.2267.bloodjournal8862267","article-title":"Long-term follow-up of minimal residual disease in leukemia patients by monitoring WT1 (Wilms tumor gene) expression levels","volume":"88","author":"Inoue","year":"1996","journal-title":"Blood"},{"issue":"2","key":"10.1016\/j.cca.2026.121290_bb0470","first-page":"230","article-title":"Quantification of Wilms\u2019 tumor 1 mRNA by digital polymerase chain reaction","volume":"107","author":"Yuki","year":"2017","journal-title":"Int. J. Hematol."},{"issue":"5","key":"10.1016\/j.cca.2026.121290_bb0475","doi-asserted-by":"crossref","first-page":"422","DOI":"10.1056\/NEJMoa1507471","article-title":"Assessment of minimal residual disease in standard-risk AML","volume":"374","author":"Ivey","year":"2016","journal-title":"N. Engl. J. Med."},{"issue":"5","key":"10.1016\/j.cca.2026.121290_bb0480","doi-asserted-by":"crossref","first-page":"1392","DOI":"10.1038\/s41375-021-01131-6","article-title":"Clinical impact of panel-based error-corrected next generation sequencing versus flow cytometry to detect measurable residual disease (MRD) in acute myeloid leukemia (AML)","volume":"35","author":"Patkar","year":"2021","journal-title":"Leukemia"},{"issue":"15","key":"10.1016\/j.cca.2026.121290_bb0485","doi-asserted-by":"crossref","first-page":"1604","DOI":"10.1182\/blood-2018-04-848028","article-title":"Next-generation sequencing-based posttransplant monitoring of acute myeloid leukemia identifies patients at high risk of relapse","volume":"132","author":"Kim","year":"2018","journal-title":"Blood"},{"issue":"4","key":"10.1016\/j.cca.2026.121290_bb0490","doi-asserted-by":"crossref","first-page":"601","DOI":"10.1111\/ejh.14151","article-title":"Droplet digital PCR for sensitive relapse detection in acute myeloid leukaemia patients transplanted by reduced intensity conditioning","volume":"112","author":"Gronlund","year":"2024","journal-title":"Eur. J. Haematol."},{"issue":"12","key":"10.1016\/j.cca.2026.121290_bb0495","doi-asserted-by":"crossref","first-page":"1273","DOI":"10.1200\/JCO.19.03011","article-title":"Impact of conditioning intensity of allogeneic transplantation for acute myeloid Leukemia with genomic evidence of residual disease","volume":"38","author":"Hourigan","year":"2020","journal-title":"J. Clin. Oncol."},{"issue":"18","key":"10.1016\/j.cca.2026.121290_bb0500","doi-asserted-by":"crossref","first-page":"1919","DOI":"10.1056\/NEJMoa074256","article-title":"MicroRNA expression in cytogenetically normal acute myeloid leukemia","volume":"358","author":"Marcucci","year":"2008","journal-title":"N. Engl. J. Med."},{"issue":"40","key":"10.1016\/j.cca.2026.121290_bb0505","doi-asserted-by":"crossref","first-page":"15535","DOI":"10.1073\/pnas.0808266105","article-title":"Distinct microRNA expression profiles in acute myeloid leukemia with common translocations","volume":"105","author":"Li","year":"2008","journal-title":"Proc. Natl. Acad. Sci. USA"},{"issue":"1","key":"10.1016\/j.cca.2026.121290_bb0510","doi-asserted-by":"crossref","first-page":"13","DOI":"10.1016\/j.ccr.2009.11.020","article-title":"DNA methylation signatures identify biologically distinct subtypes in acute myeloid leukemia","volume":"17","author":"Figueroa","year":"2010","journal-title":"Cancer Cell"},{"issue":"25","key":"10.1016\/j.cca.2026.121290_bb0515","doi-asserted-by":"crossref","first-page":"2424","DOI":"10.1056\/NEJMoa1005143","article-title":"DNMT3A mutations in acute myeloid leukemia","volume":"363","author":"Ley","year":"2010","journal-title":"N. Engl. J. Med."},{"issue":"5","key":"10.1016\/j.cca.2026.121290_bb0520","doi-asserted-by":"crossref","first-page":"871","DOI":"10.1038\/s41588-023-01376-0","article-title":"Single duplex DNA sequencing with CODEC detects mutations with high sensitivity","volume":"55","author":"Bae","year":"2023","journal-title":"Nat. Genet."},{"issue":"11","key":"10.1016\/j.cca.2026.121290_bb0525","doi-asserted-by":"crossref","first-page":"1058","DOI":"10.1056\/NEJMoa0903840","article-title":"Recurring mutations found by sequencing an acute myeloid leukemia genome","volume":"361","author":"Mardis","year":"2009","journal-title":"N. Engl. J. Med."},{"issue":"12","key":"10.1016\/j.cca.2026.121290_bb0530","doi-asserted-by":"crossref","first-page":"1079","DOI":"10.1056\/NEJMoa1112304","article-title":"Prognostic relevance of integrated genetic profiling in acute myeloid leukemia","volume":"366","author":"Patel","year":"2012","journal-title":"N. Engl. J. Med."},{"issue":"12","key":"10.1016\/j.cca.2026.121290_bb0535","doi-asserted-by":"crossref","first-page":"2810","DOI":"10.3324\/haematol.2022.282034","article-title":"The present and future of measurable residual disease testing in acute myeloid leukemia","volume":"107","author":"Blachly","year":"2022","journal-title":"Haematologica"},{"issue":"22","key":"10.1016\/j.cca.2026.121290_bb0540","doi-asserted-by":"crossref","first-page":"e154","DOI":"10.1093\/nar\/gkv795","article-title":"DREAMing: a simple and ultrasensitive method for assessing intratumor epigenetic heterogeneity directly from liquid biopsies","volume":"43","author":"Pisanic","year":"2015","journal-title":"Nucleic Acids Res."},{"issue":"3","key":"10.1016\/j.cca.2026.121290_bb0545","doi-asserted-by":"crossref","DOI":"10.3390\/biomedicines12030599","article-title":"Measurable residual disease detection in acute myeloid Leukemia: current challenges and future directions","volume":"12","author":"Moritz","year":"2024","journal-title":"Biomedicines"},{"key":"10.1016\/j.cca.2026.121290_bb0550","doi-asserted-by":"crossref","DOI":"10.3389\/fonc.2022.999822","article-title":"Concordance in measurable residual disease result after first and second induction cycle in acute myeloid leukemia: an outcome- and cost-analysis","volume":"12","author":"Tettero","year":"2022","journal-title":"Front. Oncol."}],"container-title":["Clinica Chimica Acta"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0009898126004729?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0009898126004729?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2026,10,15]],"date-time":"2026-10-15T16:29:19Z","timestamp":1792081759000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0009898126004729"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2027,2]]},"references-count":110,"alternative-id":["S0009898126004729"],"URL":"https:\/\/doi.org\/10.1016\/j.cca.2026.121290","relation":{},"ISSN":["0009-8981"],"issn-type":[{"value":"0009-8981","type":"print"}],"subject":[],"published":{"date-parts":[[2027,2]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Digital droplet PCR and liquid biopsy in acute myeloid Leukemia: bridging translational research and clinical practice","name":"articletitle","label":"Article Title"},{"value":"Clinica Chimica Acta","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.cca.2026.121290","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2026 Elsevier B.V. All rights are reserved, including those for text and data mining, AI training, and similar technologies.","name":"copyright","label":"Copyright"}],"article-number":"121290"}}